Kezar Life Sciences Inc expected to post a loss of $2.39 a share - Earnings Preview

Kezar Life Sciences

08/08/2025 12:08

Kezar Life Sciences Inc KZR.OQ KZR.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Kezar Life Sciences Inc is for a loss of $2.39 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Kezar Life Sciences Inc is $12.50, about 68.2% above its last closing price of $3.98

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-2.62
-2.60
-2.27
Beat
12.9
Dec. 31 2025
-2.59
-2.88
-2.77
Beat
4
Sep. 30 2024
-3.27
-3.15
-2.78
Beat
11.7​
Jun. 30 2024
-3.39
-3.20
-2.70
Beat
15.7
​​Mar. 31 2024
-3.33
-3.33
-3.00
Beat
9.9
Dec. 31 2023
-4.30
-3.80
-4.40
Missed
-15.8​
Sep. 30 2023
-3.58
-3.49
-3.20
Beat
8.4
Jun. 30 2023
-3.21
-3.20
-3.40
Missed
-6.2

This summary was machine generated August 8 at 11:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)